The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Dr. Metz on Somatostatin Analogs and Emerging Agents in NETs Landscape

David C. Metz, MD
Published Online: 4:18 PM, Thu October 19, 2017

David C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.